Please login to the form below

Not currently logged in
Email:
Password:

CEPI

This page shows the latest CEPI news and features for those working in and with pharma, biotech and healthcare.

China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine

China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine

COVAX is the vaccine pillar of the WHO’s ACT Accelerator – a collaborative initiative co-led by Gavi, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI) that is working

Latest news

More from news
Approximately 3 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Developing a COVID-19 vaccine Developing a COVID-19 vaccine

    In March the CEPI called for new funding for the expansion of potential vaccine candidates, saying that $2bn is needed to support the development of a successful COVID-19 vaccine. ... stockpiled and ready for trials and emergency authorisation should an

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....